The following is an overview of the evidence evaluating the risks and benefits of noninvasive methods of ventilation in premature infants. This evidence is taken from a variety of reviews in the Cochrane Library that address the issue of continuous distending pressure (CDP) or nasal intermittent positive pressure ventilation (NIPPV).
Introduction
In both continuous distending pressure (CDP) and nasal intermittent positive pressure ventilation (NIPPV), infants receive continuous distending pressure. CDP improves pulmonary function by increasing functional residual capacity, preventing alveolar collapse, increasing transpulmonary pressure and compliance, decreasing intrapulmonary shunt, improving distribution of ventilation, and conserving surfactant. There are a broad number of indications to consider applying distending pressure to infants. Most of the research regarding the clinical use of distending pressure, including the initial introduction of CDP in the 1970s, was in infants with respiratory distress syndrome. However, CDP may be effective in a variety of disease entities including pulmonary edema, apnea and bradycardia, meconium aspiration, bronchiolitis, bronchopulmonary dysplasia, tracheomalacia and partial paralysis of the diaphragm. CDP may be useful in providing respiratory support after extubation unrelated to the underlying pulmonary diagnosis.
Since the 1970s, multiple clinical trials have evaluated the usefulness of CDP. The following discussion is an overview of the evidence evaluating the risks and benefits of noninvasive methods of ventilation in premature infants. This evidence is taken from a variety of reviews in the Cochrane Library that address the issue of CDP or NIPPV.
Continuous distending pressure
Although CDP was first introduced in the 1970s, it did not gain widespread acceptance in neonatal intensive care units until the late 1980s. Renewed interest in CDP probably began with a survey of centers who were all recipients of score grants from the National Institutes of Health (NIH) for lung disease. 1 The survey noted a great deal of variation in the incidence of bronchopulmonary dysplasia (BPD; defined as oxygen at 28 days). The center with the absolute lowest rate of BPD, Columbia, had the most unique approach to the stabilization of the sick newborn. Their policy included stabilization on continuous positive airway pressure (CPAP) using short nasal prongs. Since then, there are many reports in the literature regarding the introduction of nasal CPAP and improvement in pulmonary outcomes. De Klerk and De Klerk 2 documented the effects of instituting a system of respiratory support based primarily on the early institution of nasal CPAP. A retrospective comparison of outcomes in infants with birth weight of 1000-1499 g was made over a 5-year period, before and after the introduction of a nasal CPAP-based approach to respiratory support. In the period following the introduction of nasal CPAP, there was a reduction in the number of infants ventilated (65 vs 14%; P<0.0001) and a reduction in the number of infants receiving surfactant (40 vs 12%; P ¼ 0.001). A decreased incidence of BPD at 28 days (11 vs 0%; P ¼ 0.02) and death or BPD at 28 days (16 vs 3%; P ¼ 0.046) was also noted.
Although there are several large studies underway or recently completed, 3 there is little evidence available from randomized controlled trials to support the prophylactic use of continuous distending pressure. Subramaniam et al. 4 have published a systematic overview of randomized controlled trials evaluating prophylactic nasal CPAP for preventing morbidity and mortality in very preterm infants. Two eligible trials reporting on a total of 312 infants were included in this review. 5, 6 There was no statistically significant differences between the CPAP and control groups for any of the outcomes studied in either of the eligible trials or in the meta-analysis. 7 report a systematic overview of trials evaluating the use of continuous distending pressure in preterm infants with respiratory distress syndrome. This review includes five studies that enrolled a total of 197 infants. [8] [9] [10] [11] [12] These studies represent a very heterogeneous collection of studies that were conducted over several decades. The standard of care differed greatly between these trials, including the use of antenatal steroids and postnatal surfactant therapy. In particular, only two of these five studies utilized CPAP, 8, 10 the other three used continuous negative pressure (CNP) as the source of distending pressure. 9, 11, 12 The application of CDP improved the outcome of infants with RDS. All five trials of CDP in infants with RDS reported on the combined outcome of death or use of any assisted ventilation. The meta-analysis supports a significant reduction in the risk of death or use of assisted ventilation in the CDP compared with the control group [typical RR 0.70 (95% CI 0.55, 0.88), typical RD À0.22 (95% CI À0.35, À0.09), NNT 5 (3, 11)]. Although none of trials found evidence of a difference in the use of IPPV between the groups, the meta-analysis showed a trend towards reduced use of IPPV in the CDP group that did not reach statistical significance [typical RR 0.81 (95% CI 0.63, 1.04)]. Importantly, the metaanalysis of all five trials supports a significant reduction in mortality [typical RR 0.52 (95% CI 0.32, 0.87), typical RD À0.15 (95% CI À0.26, À0.04), NNT 7 (4, 25)]. In particular, this effect was seen in infants weighing greater than 1500 g at birth.
Some complications were noted to be associated with the application of CDP in infants with RDS. Although no individual trial showed a significant increase in the risk of pneumothorax, the meta-analysis supports an increased risk of pneumothorax in the CDP group [typical RR 2.63 (95% CI 1.25, 5.54), typical RD 0.14 (95% CI 0.04, 0.23), NNH 7 (4, 24)]. There is no evidence of difference between the treatment and control groups in the duration of oxygen therapy or bronchopulmonary dysplasia. There are limited data on intracranial hemorrhage, and no data available on long term follow up. Unfortunately, there are too few trials of CPAP as the source of CDP to allow for any meaningful subgroup analysis. Although significant clinical benefit is noted in this review, it is difficult to know whether the results are applicable to current practice since these studies were done decades ago, before the routine use of antenatal steroids. In addition, the majority of studies were done using CNP, a CDP device no longer in clinical use.
The timing of application of continuous distending pressure has been studied in six randomized controlled trials. [13] [14] [15] [16] [17] [18] These six trials enrolled 165 infants with RDS. A systematic review of these trials was conducted by Ho et al. 19 These trials are also somewhat dated, with the majority being from the 1970s. Trials used either CNP or CPAP. None of the six individual trials showed that early application of CDP compared to delayed CDP resulted in a significant reduction in the requirement for IPPV. However, the meta-analysis of all six trials supports a statistically significant reduction in use of IPPV in the early CDP group [typical RR 0.55 (95% CI 0.32, 0.96), typical RD À0.16 (95% CI À0.28, À0.03), NNT 6 (4, 33)]. There was no significant reduction in overall mortality [typical RR 0.68 (95% CI 0.34, 1.38), typical RD À0.07 (95% CI À0.18, 0.04)]. Despite concerns from the previous trials of CDP in infants with RDS, there was no significant effect of early CDP on the risk of pneumothorax. No significant difference in the risk of BPD at 28 days was noted in the one study that reported this outcome. 18 The authors did not report the outcomes IVH, necrotizing enterocolitis (NEC) and chronic lung disease (CLD) at 36 weeks. Additionally, none of the studies report on physical growth or neurodevelopmental follow up assessment.
Subgroup analyses were completed for the four studies using CPAP 13, 15, 16, 18 and the remaining two studies using CNP. 14, 17 Early application of CDP led to a significant reduction in use of IPPV in the two studies using CNP [typical RR 0.12 (95% CI 0.02, 0.85), typical risk difference (RD) À0.36 (95% CI À0.58, À0.14), NNT 3 (2, 7)] but not in the four studies using CPAP [typical RR 0.77 (95% CI 0.43, 1.38), typical RD À0.08 (95% CI À0.23, 0.08)]. There was no evidence at 28 days of effect on mortality, pneumothorax or BPD in any of the subgroups.
Stabilization after extubation is probably the most common use of continuous distending pressure. Accordingly, there is a substantial amount of evidence to support this practice. Davis et al. 20 performed a systematic review of trials that evaluated the use of CDP in the stabilization of infants after extubation. There are eight trials that address the use of CDP as a method to stabilize infants after extubation. [21] [22] [23] [24] [25] [26] [27] [28] Most of these trials occurred in the 1990s. Infants extubated to nasal CPAP experienced a reduction in respiratory failure, leading to the need for additional ventilator support [typical RR 0.62 (95% CI 0.49, 0.77), typical RD À0.17 (95% CI À0.24, À0.10)]. Based on this estimate, treatment of six infants (95% CI 4, 10 infants) with nasal CPAP is required to prevent one extubation failure. In fact, the impact of nasal CPAP in preventing respiratory failure after extubation is probably greater than this estimate, since in four of the studies, nasal CPAP was used as ''rescue'' therapy for infants failing stabilization without nasal CPAP and therefore ''dilutes'' the effect on respiratory failure. In the five trials that reported on the need for supplemental oxygen at 28 days, no significant difference in the rate of oxygen use at 28 days was noted [typical RR 1.00 (95% CI 0.81, 1.24), typical RD 0.00 (95% CI À0.09, 0.09)]. Nasal CPAP is clearly effective at preventing respiratory failure after extubation. Although the use of nasal CPAP after extubation is a well accepted practice, further research would be appropriate to address patient selection and optimal CPAP device.
As many of the studies of CDP have been conducted, new and innovative therapies have been introduced that help ameliorate RDS and improve the pulmonary status of infants at risk of RDS. The use of antenatal steroids and postnatal surfactant administration is now part of the standard of care of these infants. For all of its appeal, one of the downsides of surfactant administration is that, based on current technology, infants must be intubated to receive treatment. This creates an apparent tension between the decision to support the infant in a noninvasive fashion versus the decision to intubate the infant and administer surfactant therapy. In fact, these treatments do not need to be viewed as mutually exclusive. Verder et al. 29 performed a multicenter trial evaluating whether intubation and administration of a single dose of surfactant before the occurrence of serious respiratory deterioration could reduce the subsequent need for mechanical ventilation. Thirty-five infants with moderate/severe respiratory distress syndrome were randomly assigned to surfactant therapy plus nasal CPAP and 33 infants to nasal CPAP alone. The need for subsequent mechanical ventilation was reduced with surfactant therapy (43% of the surfactant-treated babies compared with 85% of the controls; P ¼ 0.003). After 28 days, two of the surfactanttreated babies had died compared with five of the control babies.
Stevens et al. 30 have performed a meta-analysis of trials that evaluated the use of early surfactant administration, brief ventilation and rapid extubation to nasal CPAP compared with continued mechanical ventilation and selective surfactant administration for preterm infants with or at risk for respiratory distress syndrome. Four randomized controlled trials, including the trial of Verder and colleagues noted above, are included in this review. [29] [30] [31] [32] [33] In these four studies, enrolled infants had signs and symptoms of RDS. Early surfactant therapy followed by nasal CPAP compared with later, selective surfactant administration for infants with RDS was associated with a significantly reduced need for mechanical ventilation [typical RR 0.70 (95% CI 0.59, 0.84)]. A trend toward a decreased risk of air leak was noted [typical RR 0.51 (95% CI 0.23, 1.10)]. 29, 33 Limited data are available regarding long-term pulmonary outcome. No significant differences are reported regarding the risk of BPD (oxygen at 28 days) or CLD (oxygen at 36 weeks postmenstrual age). Only Verder et al. 29 reported on neonatal mortality. In this study, a trend towards decreased mortality with early surfactant therapy was noted [RR 0.38 (95% CI 0.08, 1.81)]. By definition, this approach to surfactant administration will increase surfactant utilization. Two studies reported the number of patients receiving surfactant. Early surfactant therapy followed by nasal CPAP compared with later, selective surfactant administration for infants with RDS was associated with more infants being exposed to surfactant treatment [typical RR 1.59 (95% CI 1.35, 1.88)]. Although three of the four included studies reported slightly shorter duration of mechanical ventilation for the early surfactant group compared with selective surfactant administration, the magnitude and significance of the effect is difficult to interpret from existing data owing to differences in how the value was calculated and reported. There was no evidence of effect on incidence of IVH, periventricular leukomalacia, pulmonary hemorrhage or NEC. In the Verder study, a trend towards a higher rate of patent ductus arteriosus requiring treatment was associated with early surfactant therapy and nasal CPAP compared with selective surfactant therapy and continued mechanical ventilation. 29 Stevens et al. 30 conclude that early surfactant treatment with extubation to nasal CPAP compared to later selective surfactant replacement and continued mechanical ventilation is associated with a reduced need for mechanical ventilation, but an increased utilization of surfactant medical therapy. The authors note that there is insufficient evidence to comment on the effect of this practice on important clinical outcomes, including chronic lung disease and mortality.
Nasal intermittent positive pressure ventilation
Another innovative approach to noninvasive ventilation is the addition of intermittent mandatory ventilation to non-invasively applied continuous distending pressure. NIPPV has been used in a variety of settings in the newborn, as far back as the 1980s. In a survey of tertiary care centers in Canada, Ryan et al. 34 reported that over 50% of centers used NIPPV. The physiological benefits of NIPPV in infants include decreased asynchronous breathing, improved tidal and minute volume and decreased inspiratory effort compared with the use of nasal CPAP alone. 35, 36 As the use of NIPPV grew in the 1980 s, reports of complications surfaced. Garland et al. 37 reported an association between the use of NIPPV and increased risk of gastrointestinal perforation.
Davis et al. 38 performed a meta-analysis on the use of NIPPV compared with nasal CPAP in preventing complications after extubation of premature infants. Three trials are included in this review. [39] [40] [41] All three trials used synchronized NIPPV. The three trials each demonstrated a statistically significant benefit for infants extubated to NIPPV regarding prevention of respiratory failure [typical RR 0.21 (95% CI 0.10, 0.45), typical RD À0.32 (95% CI À0.45, À0.20)]. This is a clinically relevant reduction in respiratory failure; only three infants (95% CI, 2-5 infants) need to be treated with NIPPV to prevent 1 extubation failure. This is a surprisingly strong result given the relatively few infants enrolled in these studies (n ¼ 159). The results are not as strong if one evaluates the rate of endotracheal reintubation. Not all NCPAP infants reaching extubation failure criteria were reintubated, as a varying proportion of infants in each trial was offered rescue therapy with NIPPV. The pooled estimate of rates of endotracheal reintubation favored NIPPV [typical RR 0.39 (95% CI 0.16, 0.97), typical RD À0.11 (95% CI À0.21, À0.01), NNT 9 (5, 83)]. In the one study that followed the number of apneic events, there was a trend towards a reduction in the number of apneic episodes/day in the NIPPV group. 39 A trend toward lower rates of CLD in infants randomized to NIPPV was noted in the two trials reporting this outcome, 39,41 but this did not reach statistical significance [typical RR 0.73 (95% CI 0.49, 1.07), typical RD À0.15 (95% CI À0.33, 0.03)]. There was no difference in duration of hospitalization. It is hard to assess the impact of NIPPV on many of these important clinical outcomes because many of the trials allowed for crossover treatment if there were signs of early respiratory failure.
No major complications were reported in any of the studies. No infant in any of the three studies had an intestinal perforation [typical RD 0.0 (95% CI À0.04, 0.04)]. Although these data do not discount the possibility of GI complications associated with NIPPV, the confidence interval is fairly narrow and predicts that at most one in 25 infants might experience this side effect.
Davis et al. 38 note that the studies that compare NIPPV with NCPAP are potentially confounded by differences in mean airway pressure (MAP) between the groups. Data regarding MAP are not reported; MAP may have been higher in the NIPPV group compared with the CPAP group. Therefore, differences in outcomes may be due simply to a higher mean airway pressure in the NIPPV group and not due to the addition of NIPPV.
In conclusion, Davis et al. 38 note that NIPPV is a useful method of augmenting the beneficial effects of CPAP in preterm infants. NIPPV reduces the risk of extubation failure much more effectively than nasal CPAP alone. Although the numbers are small, the analysis notes an absence of GI side effects that were reported in previous cases. The authors suggest that future trials should enroll sufficient infants to detect differences in important outcomes such as chronic lung disease and GI perforation.
Another potential application of NIPPV is in the treatment of infants with persistent apneic episodes. Lemyre et al. 42 performed a systematic review of trials that evaluated NIPPV compared with nasal CPAP for apnea of prematurity. Two trials identified examined the short term (4-6 h) effects of nasal CPAP and NIPPV in treating apnea of prematurity. 34, 43 Both trials evaluated ''failure of therapy'', defined as the need for additional ventilator support during the 4-6 h period of the study. No infants were ''rescued'' by crossover to the alternative mode of treatment; any infant requiring additional support received endotracheal intubation. Both trials reported this outcome, but only one infant (randomized to nasal CPAP) needed intubation [RR 0.30 (95% CI 0.01, 6.84), RD À0.029 (95% CI À0.120, 0.062)]. Few changes could be documented regarding the impact of NIPPV on apnea. Ryan et al. 34 reported no significant decrease in the rate of apnea (events/hour) with NIPPV as compared with NCPAP [(MD À0.10 (95% CI À0.53, 0.33)]. However, Lin et al. 43 noted a statistically significantly greater reduction in the rate of apnea in the NIPPV group [weighted mean difference (WMD) À1.19 (95% CI À2.31, À0.07)]. No attempt was made to assess endotracheal intubation beyond the trial period, long-term clinical outcome or complications such as gastrointestinal hemorrhage.
Conclusion
In preterm infants with RDS, continuous distending pressure, either a CPAP or CNP, is associated with a reduction in respiratory failure and mortality. In trials carried out in the era before antenatal steroids and postnatal surfactant treatment, distending pressure was associated with an increased rate of pneumothorax. There is no evidence currently available from recent randomized controlled trials to inform our decision, but none of the data from various nonrandomized studies support this concern.
Earlier application of distending pressure in infants with RDS has a clinical benefit in that it reduces the subsequent use of mechanical ventilation and may be useful in preventing some of the adverse effects associated with being on mechanical ventilation. Prophylactic application of nasal CPAP, although probably the most exciting potential application, is still unproven. There are many trials that are soon to be completed that will help inform our decision regarding this application. The combination of early surfactant therapy with rapid extubation to CPAP may prove to be a useful approach in infants either at risk for or having respiratory distress syndrome. This approach has been shown to reduce the need for mechanical ventilation, and may also reduce the risk of pneumothorax. There is insufficient evidence at present to evaluate the more important clinical outcomes such as chronic lung disease.
Although few studies have evaluated the use of NIPPV, this therapy may be superior to the use of nasal CPAP alone in preventing extubation failure and may prove to be the most effective noninvasive method of respiratory support. All of these therapies need further testing to refine our estimate of the effects and to determine the most effective approach to care.
